Course of Depression During the Initiation of Interferon Beta-1a Treatment for Multiple Sclerosis
Open Access
- 1 October 1999
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Neurology
- Vol. 56 (10) , 1263-1265
- https://doi.org/10.1001/archneur.56.10.1263
Abstract
INTERFERON beta-1a is approved by the Food and Drug Administration for treatment of patients with relapsing forms of multiple sclerosis (MS). Interferon beta-1a is well tolerated. Only 4% of the actively treated patients in an interferon beta-1a phase 3 clinical trial discontinued injections because of adverse effects.1 In clinical practice, 11% discontinue within 4 months of initiating treatment.2Keywords
This publication has 1 reference indexed in Scilit: